The increasing incidence of genetic and rare diseases is a major factor driving revenue growth in the Antisense ...

Biogen, for example, gained familiarity with such approach through its work with Ionis Pharmaceuticals, and even identified Dravet Syndrome as a good target for Ionis’ antisense tech back in ...

Biogen has bolstered its pipeline by licensing ex-US rights to a drug for Dravet syndrome – a rare form of epilepsy – from Stoke Therapeutics in a deal that included an upfront payment of $165 ...

Additional programs include BIIB080, a tau-targeting therapy for Alzheimer’s, and zorevunersen, currently in Phase 3 for Dravet syndrome. RBC also highlighted upcoming data for dapirolizumab pegol, ...

It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the ...

It’s mind-blowing what used to set them off." Faith had her first seizure at five months old and was diagnosed with Dravet Syndrome at 15 months after repeated emergency hospital visits.

Biogen's early-stage spinal muscular atrophy drug salanersen showed safety, motor improvements and 70% reduction in neurodegeneration markers after one-year dosing.

The global Oligonucleotide Synthesis Market is valued at USD 7.78 Billion in 2024 and is projected to reach a value of USD 21 ...

The pivotal trial for Neurogene's Rett syndrome gene therapy makes use of baseline controls and a rigorous endpoint that ...

It’s bedtime, but your legs feel like they need to move as soon as you lie down. Sound familiar? You may have restless legs syndrome.

“Restless legs syndrome is a neurological disorder that is characterized by a need to move that is oftentimes associated with an uncomfortable feeling,” said Dr. John Winkelman, chief of the ...

Biogen (BIIB) Q1 CY2025 Highlights: Revenue: $2.43 billion vs analyst estimates of $2.24 billion (6.1% year-on-year growth, 8.6% beat) Adjusted EPS: $3.02 vs analyst estimates of $2.99 (1% beat ...